Blair William & CO Cellectis S.A. Transaction History

Blair William & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $109,336 - $175,266	-13,650 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.94 - $16.09 $17,910 - $24,135	-1,500 Reduced 9.9%	13,650 $172,000
Q2 2021 Aug 12, 2021	BUY	$14.36 - $20.93 $10,770 - $15,697	750 Added 5.21%	15,150 $234,000
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $45,475 - $83,125	2,500 Added 21.01%	14,400 $291,000
Q4 2020 Feb 09, 2021	BUY	$15.87 - $31.64 $188,853 - $376,516	11,900 New	11,900 $322,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.